RE
STOK icon

RBC Europe’s Stoke Therapeutics STOK Stock Holding History

RBC Europe’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-92
Closed -$2.34K – 1089
2021
Q3 		$2.34K Hold
92
– – ﹤0.01% 1112
2021
Q2 		$3.1K Hold
92
– – ﹤0.01% 1089
2021
Q1 		$3.57K Hold
92
– – ﹤0.01% 1019
2020
Q4 		$5.7K Hold
92
– – ﹤0.01% 954
2020
Q3 		$3.08K Buy
+92
New +$2.63K ﹤0.01% 950

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

RBC Europe's STOK Position: Q4 2021 in Review

RBC Europe sold out of Stoke Therapeutics (STOK) in Q4 2021, closing a stake of 92 shares — an estimated $2.34K sold.

RBC Europe first reported a position in STOK in Q3 2020 and held it in 5 quarters. The position peaked at $5.7K in Q4 2020. 94 funds tracked by Wall St. Rank hold STOK as of Q4 2021.

  • RBC Europe reported no remaining Stoke Therapeutics position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 92 Stoke Therapeutics shares in Q4 2021, an estimated $2.34K.
  • RBC Europe first reported a position in Stoke Therapeutics in Q3 2020 and held it in 5 quarters.
  • RBC Europe's Stoke Therapeutics position peaked at $5.7K in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.